人肺癌组织中鸟苷酸解离抑制因子-2的表达和意义

目的研究鸟苷酸解离抑制因子-2（LyGDI）在肺癌组织中的表达及临床意义。方法用蛋白免疫印迹法（WB）和免疫组织化学法检测分析肺癌、癌旁组织和正常肺组织中的LyGDI蛋白表达。结果46份配对组织标本中，LyGDI在35份肺癌组织中的表达明显高于癌旁组织和正常组织，11份表达差异不明显[R=76.1%（有差异例数/总例数）]；肺癌组织中的SCLC与NSCLC表达差异无统计学意义（P＞0.05）。在SCLC中，鳞癌与腺癌也没有显著差异，而淋巴结转移组织差异有统计学意义（P＜0.05）。结论肺癌组织中LyGDI蛋白的表达与淋巴结转移存在相关性，与临床病理类型无相关性。LyGDI可能与肺癌的发生、发展有关。

Expression of Inhibitor of Guanine Nucleotided Dissociation for Rho Proteins in Human Lung Cancer and Its Clinical Significance

Objective To investigate the role of an inhibitor of guanine nucleotided dissociation for Rho proteins (LyGDI ) in human lung cancer and to evaluate its clinical significance. Methods The differenti-cal protein expression of LyGDI among lung cancer and its corresponding normal lung tissue and lung tissue was analyzed with western blotting hybridization and immunohistochemistry stain by using well characterized monoclonal antibodies. Results The results of western blotting suggested that the expression of LyGDI polycloral was significantly up-regulated in lung cancer compared with the corresponding normal lung issue and lung tissue in 35cases (P<0. 05), but it wasn't significantly up-regulated in 11 cases. It was not associated with SCLC and NSCLC differentiation of lung cancer. In NSCLC, the expression of LyGDI did not seem to vary between the squamous carcinoma and adenocarcinoma, but it was associated with lymph node metasis . Conclusion The up-regulation of LyGDI is marked correlated with the metasis and histology of lung cancer, but not with clinical and pathological types. LyGDI may play a role in lung cancer.